logo
  

BioMarin's Long-term Clinical Data On Severe Hemophilia A Show Continued, Clinical Benefit

BioMarin Pharmaceutical Inc.'s (BMRN) long-term clinical data from the ongoing phase 1/2 study of valoctocogene roxaparvovec in adults with Severe Hemophilia A demonstrated continued, durable clinical benefit.

BioMarin announced the new data from its open-label Phase 1/2 study during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.

Five-year and four-year post-treatment follow-up of the 6e13 vg/kg and 4e13 vg/kg cohorts, respectively, showed a sustained treatment benefit of valoctocogene roxaparvovec. All participants in both cohorts remain off prophylactic Factor VIII treatment.

The company noted that phase 1/2 and subset of pivotal GENEr8-1 studies demonstrated consistent bleed control following treatment with valoctocogene roxaparvovec.

Overall, the safety profile of valoctocogene roxaparvovec in the Phase 1/2 study remains consistent with previously reported data with no delayed-onset treatment related adverse events. All participants continue to remain off corticosteroids since the first year. No participants developed inhibitors to Factor VIII, and no participants withdrew from the study. No participants have developed thrombotic events, the company said.

The most common adverse events associated with valoctocogene roxaparvovec occurred early after a single infusion and included short-lived infusion-associated reactions and transient, asymptomatic, and mild to moderate rise in the levels of certain proteins and enzymes measured in liver function tests with no long-lasting clinical sequelae.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Nestle USA Inc., affiliated to Swiss food and beverage giant Nestle SA, is recalling around 27,872 pounds of frozen DiGiorno Crispy Pan Crust pepperoni pizza citing misbranding and undeclared soy protein, a known allergen, according to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS. Eli Lilly and Co. is recalling one lot of GLUCAGON Emergency Kit for low blood sugar to the consumer/user level citing loss of potency, the U.S. Food and Drug Administration announced. The recall involves lot D239382D with expiration date of April 2022 of Glucagon Emergency Kit containing 1mg of freeze-dried (lyophilized) product in a 3 mL vial and a pre-filled diluent syringe. Twitter has rolled out the tipping feature called "Tips" for everyone around the globe using the microblogging site with more payment options to choose from, including cryptocurrencies such as Bitcoin. This is a new way for people to receive and show support on Twitter with money. The feature is currently available on iOS and will be available on Android over the coming weeks.
Follow RTT